XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

NCT05184322 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of an oral tablet called ecnoglutide in healthy adults to see how well it is tolerated and how it behaves in the body.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 87 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2022-04 · est. completion 2025-03

Where 1 site · Australia

What this study is testing ClinicalTrials.gov NCT05184322 ↗

Description as written by the study sponsor.

XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.

Treatments tested

T2026 also known as Absorption enhancer excipient Drug

Once daily for 15 days.
Placebo Drug

Once daily for 15 days.
Oral ecnoglutide tablet also known as GLP-1 analogue, XW004 Drug

Once daily for 6 weeks.
Oral ecnoglutide tablet also known as GLP-1 analogue, XW004 Drug

Once daily and titrated up in concentration to once every week during maintenance period.
Oral ecnoglutide tablet also known as GLP-1 analogue, XW004 Drug

Once daily for 15 days.
Oral ecnoglutide tablet also known as GLP-1 analogue, XW004 Drug

Once daily for 15 days.
Oral ecnoglutide tablet also known as GLP-1 analogue, XW004 Drug

Once daily for 15 days.
Oral ecnoglutide tablet also known as GLP-1 analogue, XW004 Drug

Once daily for 15 days.
T2026 also known as Absorption enhancer excipient Drug

Once daily for 6 weeks.
Placebo Drug

Once daily for 6 weeks.
T2026 also known as Absorption enhancer excipient Drug

Once daily to once weekly for 12 weeks.
Placebo Drug

Once daily to once weekly for 12 weeks.

Main thing measured	Number and percentage of treatment emergent adverse events (TEAEs) and serious adverse events (SAE)
Sponsor	Sciwind Biosciences APAC CO Pty. Ltd.
Conditions studied	Obesity, Type 2 Diabetes Mellitus
GLP-1 drugs	ecnoglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05184322 ↗